stockrow
Monday 9 November 2026
Export ABOS’s income statement to Excel — free account
Acumen Pharmaceuticals, Inc.
ABOS- EPS
- +20.3%
- Free cash flow
- +12.6%
- Total debt
- −14.3%
Quarter to September 2026, against a year earlier
0.22
0.01
+4.76%
Follow ABOS
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | — | — | — |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
3.89 | 4.39 | 2.35 | 1.74 | |
Current Ratio |
4.07 | 4.55 | 2.47 | 1.89 | |
Net Debt/EBITDA |
3.42 | 4.62 | 2.40 | 2.03 | |
Debt/Assets |
25.37% | 23.23% | 27.21% | 30.70% | |
Debt/Equity |
0.44 | 0.35 | 0.55 | 0.76 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.76 | 1.16 | 0.55 | 1.05 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
(23.18) | (19.78) | (29.76) | (25.84) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.32) | (0.38) | (0.25) | (0.37) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.32) | (0.38) | (0.25) | (0.37) | |
Cash per Share |
1.93 | 2.03 | 1.53 | 1.09 | |
Shareholders Equity per Share |
1.16 | 1.38 | 0.79 | 0.48 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.16 | 1.38 | 0.79 | 0.48 | |
Free Cash Flow |
(19.10) | (24.13) | (18.07) | (26.65) | |
Working Capital |
92.25 | 103.87 | 68.67 | 40.05 | |
Capital Expenditures |
0.00 | — | — | — | |
Net Current Asset Value |
69.85 | 86.94 | 56.77 | 34.18 | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
0.00 | — | — | — | |
| Other line items | |||||
Average Payables |
3.10 | 1.36 | 7.74 | 3.37 | |
Average Assets |
180.91 | 169.05 | 143.95 | 113.89 | |
Average Common Equity |
126.12 | 121.50 | 87.17 | 63.89 |
Columns are period end dates · fundamentals updated 2 Nov 2026